These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 7281107)

  • 1. Measurement of fibrinopeptide A in patients treated with phenprocoumon.
    Harenberg J; Haas R; Zimmermann R
    Thromb Haemost; 1981 Jun; 45(3):282-4. PubMed ID: 7281107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma hypercoagulability after termination of oral anticoagulants.
    Harenberg J; Haas R; Zimmermann R
    Thromb Res; 1983 Mar; 29(6):627-33. PubMed ID: 6857601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
    Murakoshi T
    Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of septic pelvic thrombophlebitis by measurement of fibrinopeptide A.
    Weiner CP; Kwaan H; Duboe F
    Am J Perinatol; 1985 Apr; 2(2):93-5. PubMed ID: 4096764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of fibrinopeptide A in human blood.
    Nossel HL; Yudelman I; Canfield RE; Butler VP; Spanondis K; Wilner GD; Qureshi GD
    J Clin Invest; 1974 Jul; 54(1):43-53. PubMed ID: 4600045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of daily administration of naproxen on the prothrombin complex activity in patients under long-term therapy with phenprocoumon.
    Petersen PB; Husted S; Mortensen A; Andreasen F
    Scand J Rheumatol; 1979; 8(1):54-6. PubMed ID: 311940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of naproxen on the thrombocyte bleeding time and on the anticoagulant treatment with phenprocoumon].
    Angelkort B
    Fortschr Med; 1978 Jun; 96(23):1249-52. PubMed ID: 658877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin activity and oral anticoagulant therapy: a preliminary study.
    Marongiu F; Sorano GG; Mameli G; Mamusa AM; Cambuli AB; Conti M; Sanna MP; Farci P; Balestrieri A
    Haemostasis; 1989; 19(3):142-6. PubMed ID: 2744630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis.
    Nossel HL
    N Engl J Med; 1976 Aug; 295(8):428-32. PubMed ID: 59314
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease.
    Yoda Y; Abe T
    Thromb Haemost; 1981 Dec; 46(4):706-9. PubMed ID: 7330820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of allopurinol with phenprocoumon in man.
    Jähnchen E; Meinertz I; Gilfrich HJ
    Klin Wochenschr; 1977 Aug; 55(15):759-61. PubMed ID: 895010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of fibrinopeptide A (FPA) in the diagnosis of low-grade intravascular coagulation and venous thromboembolism.
    Van Mourik JA
    Haematologica; 1981 Jun; 66(3):259-68. PubMed ID: 6793455
    [No Abstract]   [Full Text] [Related]  

  • 14. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy.
    Peuscher FW; Cleton FJ; Armstrong L; Stoepman-van Dalen EA; van Mourik JA; van Aken WG
    J Lab Clin Med; 1980 Jul; 96(1):5-14. PubMed ID: 7391657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood.
    Budzynski AZ; Marder VJ
    Thromb Diath Haemorrh; 1975 Dec; 34(3):709-17. PubMed ID: 1209541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased fibrinopeptide A after prothrombin complex concentrates.
    Viganó S; Cattaneo M; Gervasoni W; Mannucci PM
    Thromb Haemost; 1980 Oct; 44(2):72-5. PubMed ID: 6779400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
    Christersson C; Oldgren J; Bylock A; Siegbahn A; Wallentin L
    Eur Heart J; 2007 Mar; 28(6):692-8. PubMed ID: 17314111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of cimetidine on action of phenprocoumon.
    Harenberg J; Zimmermann R; Staiger C; de Vries JX; Walter E; Weber E
    Eur J Clin Pharmacol; 1982 Oct; 23(4):365-7. PubMed ID: 7173307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen survival and fibrinopeptide A in acute leukemia.
    Castaman G; Galloni E; Dri AV; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):52-6. PubMed ID: 8039760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.